A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Baricitinib (Primary) ; Triamcinolone
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 14 Sep 2017 Primary endpoint: Proportion of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Index (EASI 50)has been met, according to an Eli Lilly media release.
    • 14 Sep 2017 Results presented in an oral presentation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Geneva, Switzerland as per an Eli Lilly media release.
    • 14 Sep 2017 Results published in an Eli Lilly Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top